CASE (NCT03836105) PHASE 4

Study of investigational cemiplimab in patients with **locally advanced or metastatic basal cell carcinoma and cutaneous squamous cell carcinoma**

Primary Objective: evaluate the safety and efficacy of cemiplimab in patients with locally advanced or metastatic BCC or CSCC in real-world clinical settings

PATIENTS WITH LOCALLY ADVANCED OR METASTATIC BCC OR CSCC (N=287)

OPEN LABEL INTERVENTION

Cemiplimab (IV)
(Not provided by study sponsor)[a]

Group 1	Group 2
CSCC	BCC

Primary Endpoints

- Objective response rate[b]
- Disease control rate[b]
- Duration of response
- Time to response
- Progression-free survival
- Overall survival
- Time to treatment failure
- Disease specific death[a]
- Safety

FIND OUT MORE

Scan here to find out more about this study at https://clinicaltrials.gov/ct2/show/NCT03836105

This information is intended for investigators interested in open clinical trials.
The use of cemiplimab described herein is investigational and has not been evaluated by any regulatory authority.
Please see full prescribing information in your country for cemiplimab.

[a]Patients will have recently initiated or be planning to initiate treatment with commercially available cemiplimab for advanced CSCC or advanced BCC in a real-world setting according to respective label indications. In addition to cemiplimab, patients may receive other therapies as deemed necessary by their physicians for the treatment of CSCC or BCC or comorbid conditions. [b]Based on investigator assessment.
BCC, basal cell carcinoma; CSCC, cutaneous squamous cell carcinoma; IV, intravenous; N, number of patients.

REGENERON®
MEDICAL AFFAIRS

CASE (NCT03836105) PHASE 4

CEMIPLIMAB

An Investigational, Fully Human PD-1 Monoclonal Antibody

Designed to block cancer cells from using the PD-1 pathway to suppress T-cell activation[1]

SELECTED INCLUSION CRITERIA[a]

- Eligible for treatment with and prescribed cemiplimab for advanced CSCC or advanced BCC

SELECTED EXCLUSION CRITERIA[a]

- Receiving cemiplimab for an indication other than advanced CSCC or advanced BCC
- Any condition that, in the opinion of the investigator, may interfere with patient's ability to participate in the study
- Patients concurrently participating in any study including administration of any investigational drug (including cemiplimab) or procedure (including survival follow up)

For more information, visit www.clinicaltrials.gov or please call [+353 (0)61 533 400 OR 844 REGN-MID].
NCT03836105
https://clinicaltrials.gov/ct2/show/NCT03836105

This information is intended for investigators interested in open clinical trials.
The use of cemiplimab described herein is investigational and has not been evaluated by any regulatory authority.
Please see full prescribing information in your country for cemiplimab.

[a]Inclusion/exclusion criteria include a summary of selected criteria. Please review the complete study design on clinicaltrials.gov for complete details.

BCC, basal cell carcinoma; CSCC, cutaneous squamous cell carcinoma; PD-1, programmed cell death protein-1.

Current per clinicaltrials.gov as of October 30, 2023.

1. Markham A, Duggan S. *Drugs*. 2018;78(17):1841-1846.
CEM-EM-0025 November 2023.

REGENERON®
MEDICAL AFFAIRS